Elixxer

Elixxer ROA

The Return on Assets (ROA) of Elixxer (ELXR.H.V) as of Oct 22, 2026 is -142.76 %. In the previous year, Return on Assets (ROA) was -264.04 % — a change of -45.93% (higher).

ROA

-142.76 %

YoY

-45.93%

Last updated:

In 2023, Elixxer's return on assets (ROA) was -142.76 %, a -45.93% increase from the -264.04 % ROA in the previous year.

The Elixxer ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2016
-97.60 CAD
Jan 1, 2017
-183.73 CAD
Jan 1, 2018
-79.71 CAD
Jan 1, 2019
-98.85 CAD
Jan 1, 2020
-47.00 CAD
Jan 1, 2021
-21.76 CAD
Jan 1, 2022
-264.04 CAD
Jan 1, 2023
-142.76 CAD
The Elixxer ROA history
YEARROAYoY
-142.76 %-45.93%
-264.04 %+1,113.68%
-21.76 %-53.72%
-47.00 %-52.45%
-98.85 %+24.01%
-79.71 %-56.62%
-183.73 %+88.24%
-97.60 %-41.37%
-166.46 %+187.33%
-57.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elixxer Stock analysis

What does Elixxer do? Elixxer Ltd. invests in cannabis-related businesses licensed for cultivation, production, and sale of cannabis and cannabis-derived products. The company focuses on medical cannabis and specialty pharmaceutical products, growing and producing medical-grade cannabis for global markets. Its brands include Viridi, Easyjoint, Freia, Little Green Pharma (LGP), and One Premium Cannabis, which are used for CBD cosmetics, natural wellness products, and pharmaceutical applications. Elixxer targets medical and wellness segments through its subsidiaries in Australia, Canada, Switzerland, Italy, and Jamaica, where it operates cultivation, extraction, and production facilities for legal cannabis products. The company generates revenue through its portfolio of cannabis investments, including nutraceutical, cosmetics, and pharmaceutical segments. Its subsidiaries LGC Finance Limited, LGC Capital EU OU, and LGC Capital Spain S.L. support its global operations, while its brands cater to consumers seeking CBD-based wellness solutions and medical cannabis products. Elixxer's focus on medical cannabis and pharmaceutical applications drives its market positioning in the global cannabis industry. Elixxer Ltd. primarily serves medical and specialty cannabis markets, with a strong emphasis on pharmaceutical-grade products. Its investments span cultivation, extraction, and production facilities across multiple countries, enabling it to supply global markets with medical cannabis and CBD-derived products. The company's brands are positioned within the wellness and pharmaceutical sectors, targeting consumers and healthcare providers interested in natural and medical cannabis solutions. Elixxer is one of the most popular companies on Eulerpool.

ROA Details

Understanding Elixxer's Return on Assets (ROA)

Elixxer's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Elixxer's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Elixxer's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Elixxer’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Elixxer stock

Return on Assets (ROA) of Elixxer is -142.76 % in 2023.

Return on Assets (ROA) of Elixxer changed from -264.04 % to -142.76 %, representing a -45.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Elixxer since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Elixxer with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Elixxer

All Key Metrics — Elixxer